On February 23, 2022 Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, reported the publication of preclinical data on its novel adjuvant in the scientific journal Vaccine (Press release, ImmuneTune, FEB 23, 2022, View Source [SID1234608861]). The published findings underline the ability of Immunetune’s proprietary adjuvant PyroVant to increase the immune response against its neoantigen cancer vaccine and the resulting profound impact on tumor growth and survival.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The publication on PyroVant in the journal Vaccine describes the development of a novel, first-in-class genetic adjuvant that greatly improves immune responses elicited by DNA cancer vaccines. Unlike other adjuvants, this DNA-encoded adjuvant induces pyroptosis, a form of inflammatory cell death that results in the release of a plethora of inflammatory molecules that together attract and stimulate immune cells crucial for the generation of an anti-tumor T cell response. When given simultaneously with a DNA vaccine encoding tumor antigens, PyroVant increases tumor-specific T cell numbers up to 8-fold, in a dose-dependent fashion. Subsequently, in a preclinical model of melanoma, the addition of PyroVant to this DNA vaccine significantly delayed tumor growth and increased survival.
"It is important to have these results peer-reviewed by the scientific community and share our mechanistic insights into this first-in-class genetic adjuvant to increase the potential impact of cancer vaccines," said Jeroen van Bergen, Chief Scientific Officer of Immunetune. "We are especially excited to have incorporated PyroVant in our neoantigen cancer vaccine NeoVAC, which is currently moving towards clinical development."
The experiments were performed in close collaboration with the Tumor Immunology group (Prof. Ossendorp) of the Department of Immunology at the Leiden University Medical Center (LUMC) in the Netherlands. Immunetune has submitted a patent application on PyroVant and has recently completed GLP toxicity studies of its DNA-based cancer vaccines in combination with PyroVant. These studies showed that both vaccine and PyroVant were well tolerated with no test article-related observations on survival, body weight and clinical pathology across the toxicity and biodistribution studies. Immunetune is now moving its lead cancer vaccine NeoVAC towards clinical studies.
The full publication is titled ‘Pyroptosis-inducing active caspase-1 as a genetic adjuvant in anti-cancer DNA vaccination’ and can be accessed on the website of the journal Vaccine here.